Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Atea closes $215m Series D round to support Covid-19 trials

The Covid-19 pandemic has encouraged Atea to re-orient its work in the direct-acting antiviral space to treat the novel coronavirus. Its work to progress its lead candidate, AT-527, which has shown efficacy in other coronaviruses and hepatitis C, into a Phase II Covid-19 study will be supported by its $215m Series D funding round.

Close
Close
Close

Go Top